Mayo Clinic Pharmacy Residency Programs

@MayoPharmRes

Official Twitter for PharmD Residency Programs. PGY1 | PGY1 Peds | PGY1/2 HSPA/MS | PGY2 CC, SOT, Am Care, EM, IM, Onc, PGx, Informatics |

Rochester, FL, AZ, WI, MN
Vrijeme pridruživanja: studeni 2019.

Tweetovi

Blokirali ste korisnika/cu @MayoPharmRes

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @MayoPharmRes

  1. . (PGY2 EM) will be presenting "Escaping Vaping: Where We Are and Where Go From Here" at Pharmacy Grand Rounds tomorrow, 2/4, at 11am in Alfred Main 459. Be sure not to miss this one!

    Poništi
  2. With interviews in full swing, Rochester PGY1 RPD has some - "if you made it to the interview, the program feels you are qualified. Fit is what's most important on interview day - don't get caught your perceived "mistakes" - focus on being yourself.

    Poništi
  3. proslijedio/la je Tweet
    31. sij

    Summer is just around the corner and so is the 2020 Pharmacy Internship! Congratulations to the following students from pharmacy schools across the US who will join us for 10-weeks! (1/10)

    Prikaži ovu nit
    Poništi
  4. Residents don't only learn new clinical knowledge each day - they also practice ongoing professional development. Today, PGY1 HSPA and his preceptor/RPD discussed the spacing effect as a technique to improve knowledge retention!

    Poništi
  5. proslijedio/la je Tweet

    Well-being Wednesday; A Residents Guide to Staying Organized. Perfect time of year to keep your drive, motivation, and organization into gear! We’ve made it half way, lets keep ourselves on track and continue to make progress everyday!

    Prikaži ovu nit
    Poništi
  6. Here's another interview ! Debra Droopad (PGY1 AZ) says "have open communication with preceptors as soon as you get an interview. Make sure to travel to the interview at least the night before in case you have car or flight issues! Good luck!"

    Poništi
  7. proslijedio/la je Tweet

    So we know Vancomycin + PTZ ⬆️AKI🛑 BUT is this duration dependent? What if we use it for <72h as empiric therapy?🤔 PharmD team ⁦⁩ shows short courses of PTZ/VAN were NOT associated with ⬆️AKI 🔑= SHORT courses

    Prikaži ovu nit
    Poništi
  8. In summary, TKI therapy has significantly ⬆️ outcomes for patients with CML, and certain patients may continue to maintain response even with discontinuation of TKI therapy 💊 Thank you ! Join us again next week to learn the latest on EVALI from 💨

    Prikaži ovu nit
    Poništi
  9. For patients who discontinue TKI therapy, ongoing monitoring is key 🔑

    Prikaži ovu nit
    Poništi
  10. Several studies have tested discontinuation of imatinib, dasatinib, and nilotimib. Treatment free response was observed in 33-61% of patients at varying lengths of follow up.

    Prikaži ovu nit
    Poništi
  11. Most patients achieve a deep molecular response which is associated with a low risk of disease progression and high rate of long-term survival benefit. Could patients maintain response with decreased adverse drug events by discontinuing TKIs?

    Prikaži ovu nit
    Poništi
  12. Asciminib is a TKI in the pipeline with a novel binding site that locks the BCR-ABL protein into an inactive confirmation. A recently published phase I study had promising results 📑

    Prikaži ovu nit
    Poništi
  13. Response to the initial agent should be routinely assessed and adjusted according to detected BCR-ABL1.

    Prikaži ovu nit
    Poništi
  14. Patients with intermediate- or high-risk score should be started on a 2nd generation TKI.

    Prikaži ovu nit
    Poništi
  15. The IRIS trial found significantly improved CML outcomes with imatinib, a 1st gen TKI; however, patients would continue to progress after 5-10 years, warranting the development of 2nd and 3rd gen agents.

    Prikaži ovu nit
    Poništi
  16. The chronic phase of CML is defined by < 15% blasts. Our goal is to maintain presenting patients within the chronic phase to prolong survival. 📈💊

    Prikaži ovu nit
    Poništi
  17. In this week’s , will discuss TKI therapy in CML. Stay tuned for live updates!

    Prikaži ovu nit
    Poništi
  18. Don't miss "A Second and Third Look at TKI Management in CML" at Pharmacy Grand Rounds today at 11am, presented by ! The presentation is open to all and live streaming in the Mayo network.

    Poništi
  19. . (PGY2 Oncology) will be presenting "A Second and Third Look at TKI Management in CML" at Pharmacy Grand Rounds tomorrow, 1/28, at 11am in Alfred Main 459. Be sure not to miss this one!

    Poništi
  20. The importance of pharmacy presence in our pediatric ED was just reported in a new publication by former ED PGY2 Gabby Anderson and team members from !

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·